Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GHSR | Q92847 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064111 | 1.00 | HTR6 (0.40) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1064112 | 1.00 | HTR6 (0.40) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1064983 | 0.86 | HTR6 (0.55) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1063412 | 0.86 | HTR6 (0.55) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1063728 | 0.86 | HTR6 (0.55) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1064015 | 0.86 | KMT2A (0.41) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1064019 | 0.86 | KMT2A (0.41) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1064017 | 0.86 | KMT2A (0.41) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1060619 | 0.82 | HTR6 (0.44) | HTR6KMT2ATHRBTP53ALDH1A1 | |
| SCHEMBL1062570 | 0.81 | GHSR (0.47) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015185-A1 | Benzofuran Compounds | BIOVITRUM AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-7820675-B2 | Benzofuran compounds | BIOVITRUM AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-20060287291-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287291-A1 | Compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885KMT2A 3728/4885THRB 1033/4885 |
| US-20110015185-A1 | Benzofuran Compounds | HTR6, HTR1F, HTR1A | HTR6 1/4885KMT2A 3354/4885THRB 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.